Barcelona Establishes €10 Million Framework Agreement for Public Security Surveillance Systems
22 Jul 2026
Standfirst: Barcelona d’Infraestructures Municipals, SA (BIMSA) has awarded a multi supplier framework agreement valued at up to €10 million for the supply, installation and maintenance of public security surveillance systems. The agreement will support future projects involving CCTV cameras, security devices, alarm connected systems and video surveillance infrastructure across Barcelona through a framework with reopening of competition. Introduction Modern cities increasingly rely on intelligent surveillance infrastructure to strengthen public safety, improve operational monitoring and support emergency response. Advanced camera systems, integrated alarm technologies and video surveillance platforms have become essential components of urban security strategies, enabling authorities to monitor public spaces while improving incident management and infrastructure protection. To support these objectives, Barcelona d’Infraestructures Municipals, SA (BIMSA) has completed a significant public procurement establishing a framework agreement for surveillance and security systems. Published as TED Contract Award Notice 508004-2026, the procurement covers the supply, installation and maintenance of cameras, security equipment, alarm connected devices and public video surveillance systems for contracts with an estimated value not exceeding €2 million per call off contract. The framework creates a structured procurement mechanism through which future public security projects can be awarded to pre qualified suppliers. Instead of launching a new procurement for every surveillance installation, BIMSA can organise future competitions among the appointed framework participants, improving procurement efficiency while maintaining competition throughout the framework period. Why This Contract Matters Urban surveillance infrastructure plays an increasingly important role in supporting smart city initiatives, protecting public assets and enhancing the safety of residents and visitors. CCTV systems, integrated security platforms and remote monitoring technologies assist public authorities in preventing crime, improving emergency coordination and protecting critical municipal infrastructure. The framework agreement enables Barcelona to maintain access to qualified suppliers capable of delivering advanced surveillance technologies as new security projects emerge. Because each future project may involve different technical requirements, the reopening of competition provides flexibility while ensuring that contracting authorities continue receiving competitive proposals throughout the framework's lifetime. The procurement also reflects the growing trend among European municipalities to establish long term procurement frameworks for technology intensive infrastructure rather than conducting separate tenders for every individual installation. This approach reduces procurement timelines while preserving transparency and compliance with European public procurement legislation. Contract Timeline Milestone Details Country Spain Contracting Authority Barcelona d’Infraestructures Municipals, SA (BIMSA) Procurement Title Supply, installation and maintenance of surveillance and security systems Procedure Open Procedure Contract Type Supplies Main CPV 35120000 - Surveillance and security systems and devices Estimated Framework Value EUR 10,000,000 Framework Duration 12 Months Publication Date 22 July 2026 Official Journal OJ S 139/2026 Contract Overview The procurement establishes a multi supplier framework agreement for the supply and installation of surveillance systems together with comprehensive maintenance services. The framework covers cameras, security equipment, alarm connected devices, monitoring systems and related technologies supporting public security operations throughout Barcelona. According to the contract award notice, the framework is designed for future contracts with an estimated value of up to €2 million per individual call off contract. Future procurement requirements will be awarded through reopening of competition among the appointed framework suppliers, enabling BIMSA to select the most appropriate contractor for each project while maintaining competitive market conditions. The procurement was conducted using the Open Procedure under Directive 2014/24/EU. The estimated value of the framework amounts to €10 million, while the procurement is covered by the WTO Government Procurement Agreement (GPA) and is not financed through European Union funds. Key Contract Details Category Information Buyer Barcelona d’Infraestructures Municipals, SA (BIMSA) Country Spain Contract Type Supplies Main CPV 35120000 - Surveillance and security systems and devices Procedure Open Procedure Framework Agreement Yes - With reopening of competition Dynamic Purchasing System No Estimated Framework Value EUR 10,000,000 Maximum Value Per Call off Contract EUR 2,000,000 Framework Duration 12 Months Legal Basis Directive 2014/24/EU EU Funding No Project Scope The framework agreement covers the supply, installation and maintenance of surveillance and security systems connected to alarm receiving centres, control centres and video surveillance platforms. The procurement includes cameras, security equipment, devices and integrated technologies supporting public security monitoring throughout the municipality. Future projects awarded under the framework may involve installation of new surveillance systems, replacement of existing equipment, upgrades to monitoring infrastructure and ongoing maintenance services. Individual technical specifications will be determined through future call off competitions conducted among the appointed framework suppliers. The framework provides Barcelona with a flexible procurement mechanism capable of supporting a broad range of public safety infrastructure projects while ensuring continued competition and compliance with public procurement regulations. About the Contracting Authority Barcelona d’Infraestructures Municipals, SA (BIMSA) is the contracting authority responsible for this procurement. As a public undertaking controlled by the local authority, BIMSA manages infrastructure related procurement and investment projects supporting the development and maintenance of municipal assets and public services across Barcelona. Through framework agreements such as this, BIMSA enables efficient delivery of infrastructure projects by establishing qualified supplier panels capable of supporting future municipal investment programmes. About the Organisations Involved The procurement was managed by Barcelona d’Infraestructures Municipals, SA (BIMSA), which also provides procurement information and serves as the organisation responsible for review related information. The Tribunal Catalán de Contratos del Sector Público acts as both the mediation and review authority for the procurement process. Five suppliers were appointed to the framework agreement following the competitive procurement process: ADTEL SISTEMAS DE SEGURIDAD S.L. MODI SEGURIDAD, S.L. ELECNOR SEGURIDAD TELEFÓNICA DEFENSA Y SEGURIDAD, S.A. SOCIETAT UNIPERSONAL UBERCROS SEGURIDAD S.L. According to the contract award notice, the successful suppliers concluded their framework contracts on 15 July 2026 and 17 July 2026. Six electronic tenders were received during the procurement, with all submissions originating from micro, small or medium sized enterprises registered within Spain.Procurement Analysis The procurement was conducted using the Open Procedure under Directive 2014/24/EU, allowing interested suppliers to compete for inclusion in a multi supplier framework agreement. Rather than awarding a single supply contract, Barcelona d’Infraestructures Municipals, SA (BIMSA) established a framework that enables future surveillance and security projects to be awarded through the reopening of competition among the selected suppliers. This procurement model combines long term supplier availability with continued competitive pricing for individual projects. The framework covers the supply, installation and comprehensive maintenance of surveillance cameras, security equipment, alarm connected devices and video surveillance systems. Individual call off contracts issued under the framework are limited to an estimated value of €2 million, while the total estimated framework value reaches €10 million. This structure provides the contracting authority with flexibility to undertake multiple security projects over the framework period without conducting a completely new procurement each time. Five suppliers were appointed to the framework following the evaluation process. Future contracts will be awarded by reopening competition among these framework participants according to the requirements of each individual project. The notice confirms that the procurement does not establish a Dynamic Purchasing System and that it is covered by the WTO Government Procurement Agreement (GPA). The project is not financed through European Union funds. The award criteria consisted of both quality and price. The procurement notice states that the detailed evaluation methodology is described in the annexes to the procurement documents, but it does not disclose the weighting assigned to each criterion. Additional Procurement Facts Item Details Contracting Authority Barcelona d’Infraestructures Municipals, SA (BIMSA) Country Spain Procedure Open Procedure Contract Type Supplies Main CPV 35120000 - Surveillance and security systems and devices Framework Agreement Yes - With reopening of competition Estimated Framework Value EUR 10,000,000 Maximum Value per Call off Contract EUR 2,000,000 Framework Duration 12 Months Dynamic Purchasing System No Award Criteria Quality and Price Number of Tenders Received 6 Government Procurement Agreement Yes EU Funding No Market and Industry Perspective Demand for integrated surveillance and security technologies continues to increase across European municipalities as cities invest in smarter public infrastructure and enhanced public safety. Modern surveillance networks combine high definition cameras, intelligent monitoring platforms, alarm systems and centralised control centres to improve situational awareness and support rapid incident response. Framework agreements have become a preferred procurement mechanism for technology intensive security projects because they provide authorities with rapid access to qualified suppliers while maintaining competition for individual contracts. This procurement model is particularly valuable where projects are delivered in phases or where future requirements cannot be fully defined at the time of the initial procurement. The Barcelona framework also reflects the growing integration of installation services and long term maintenance into a single procurement, ensuring that surveillance infrastructure remains operational throughout its lifecycle while reducing administrative complexity for contracting authorities. Economic Significance The framework agreement represents an estimated procurement programme worth up to €10 million, supporting continued investment in Barcelona's public security infrastructure. Although individual projects will be awarded separately, the framework establishes a long term procurement vehicle capable of supporting multiple surveillance initiatives throughout the agreement period. Investment in public security technologies extends beyond equipment purchases. It supports specialist system integrators, security technology manufacturers, installation contractors, maintenance providers and software specialists while contributing to safer public environments and more resilient municipal infrastructure. Future Procurement Opportunities The framework is expected to generate future procurement activity for a broad range of security technologies and associated services, including: Public CCTV camera systems Video surveillance platforms Integrated alarm systems Security control centre equipment Access control technologies Networked security devices Monitoring software Preventive maintenance services System upgrades and modernisation Installation and commissioning services Opportunities for Suppliers The procurement demonstrates continuing opportunities for organisations operating within the electronic security and smart infrastructure sectors. Security system integrators CCTV equipment manufacturers Video surveillance solution providers Alarm system specialists Telecommunications infrastructure companies Network integration providers Security maintenance contractors Control room technology suppliers Smart city technology companies Electronic security consultants What Businesses Should Watch Municipal authorities across Europe continue expanding investments in public surveillance infrastructure as part of wider smart city and public safety initiatives. Suppliers should monitor future reopening of competition under this framework as well as similar municipal security programmes that increasingly favour multi supplier framework agreements. Companies capable of delivering integrated solutions covering equipment supply, installation, systems integration and long term maintenance are expected to remain well positioned for future public sector security procurements. SpainTenders.com Procurement Intelligence From a procurement intelligence perspective, this framework highlights several important trends within European public security procurement. Municipal authorities continue investing in integrated surveillance infrastructure. Framework agreements remain the preferred procurement model for recurring technology projects. Multi supplier frameworks promote competition throughout the contract lifecycle. Security procurements increasingly combine equipment supply with long term maintenance. Public surveillance systems remain a strategic component of smart city development. Future call off competitions create ongoing opportunities for appointed suppliers. Supplier Takeaways Develop integrated surveillance and security capabilities. Strengthen expertise in CCTV and video management technologies. Offer complete installation and lifecycle maintenance services. Monitor future call off competitions issued under the framework. Maintain compliance with European public procurement requirements. Invest in smart city and public safety technology solutions. Key Takeaways Barcelona established a €10 million framework agreement for surveillance and security systems. The procurement covers supply, installation and maintenance of public security technologies. Five suppliers were appointed to the framework agreement. Future contracts will be awarded through reopening of competition. The framework supports projects valued up to €2 million per call off contract. The procurement was conducted under Directive 2014/24/EU using the Open Procedure. Conclusion Barcelona d’Infraestructures Municipals, SA has established a comprehensive procurement framework that strengthens the city's ability to deliver future surveillance and public security projects efficiently. By appointing multiple qualified suppliers and adopting a framework agreement with reopening of competition, BIMSA has created a flexible procurement model capable of responding to evolving municipal security requirements. The agreement also reflects broader European procurement trends, where public authorities increasingly rely on long term framework arrangements to support technology driven infrastructure projects. As cities continue investing in smart security systems, integrated monitoring platforms and public safety technologies, similar framework agreements are expected to remain central to municipal procurement strategies. Source: TED Contract Award Notice: 508004-2026; Official Journal of the European Union (OJ S 139/2026); Publication Date: 22 July 2026
View Details
Andalusia Splits Its Record Flu Vaccine Order Three Ways - Sanofi, Seqirus and AstraZeneca All Get a Piece
21 Jul 2026
Standfirst Ahead of what regional health officials are calling a record influenza vaccination campaign, the Andalusian Health Service has awarded its 2026-2027 flu vaccine framework across three manufacturers, Sanofi Aventis, Seqirus Spain and AstraZeneca FarmacĂ©utica, rather than a single supplier. The split, worth up to €47.1 million across two possible campaign years, reflects a vaccination programme that increasingly needs different vaccine formulations for different age groups rather than one product for everyone. Introduction Not every vaccine campaign can run on a single product and Andalusia's seasonal flu programme is a clear illustration of why. A healthy 30 year old, a frail 85 year old in residential care and a toddler being vaccinated at nursery all need meaningfully different flu vaccines, different antigen doses, different formulations, in the toddler's case an entirely different delivery method (a nasal spray rather than an injection). The Andalusian Health Service's latest flu vaccine procurement reflects that reality directly: rather than awarding one contract to one manufacturer, it has split its supply framework across three companies, each covering different lots tailored to different parts of the vaccination programme.The framework, structured across five lots grouped into three award decisions, will supply the region's flu vaccination campaign for the 2026-2027 season, with an option to extend into 2027-2028. Sanofi Aventis, Seqirus Spain and AstraZeneca FarmacĂ©utica Spain were each awarded different portions of the programme, together valued at just over €21.3 million for the base 2026-2027 campaign, against a maximum possible framework ceiling of €47.1 million if the option to extend is exercised. Why This Contract Matters Andalusian health officials have described the coming campaign as one of their most ambitious yet, targeting more than two million vaccinated residents and initially budgeting for close to 1.955 million doses, with built in flexibility to expand supply by up to 20% depending on how the vaccination pace, epidemiological conditions and clinical need develop through the season. That kind of scale and flexibility only works if the underlying supply contract is structured to match the genuine diversity of the population being vaccinated.This is also a useful illustration of how modern vaccination programmes have moved well past "one flu shot for everyone." Andalusia's current flu immunisation strategy uses distinct vaccine types for distinct groups: a nasal, live attenuated vaccine for young children, a high antigen formulation for very elderly or institutionalised residents and standard formulations for the broader adult population, each with different manufacturers, different production processes and different supply economics. A single supplier contract simply could not serve every one of those needs efficiently.Contract Timeline Date Milestone — Underlying framework agreement established (referenced notice 226611-2026) 30 September 2025 Previous season's (2025-2026) flu vaccination campaign begins, providing operational context for this framework's timing 24 June 2026 Winners selected across all three lot groups 16 July 2026 Contracts concluded with Sanofi Aventis, Seqirus Spain and Astrazeneca FarmacĂ©utica Spain 20 July 2026 Award notice dispatched to the EU Publications Office 21 July 2026 Notice published in OJ S 138/2026 Autumn 2026 2026-2027 flu vaccination campaign expected to begin Contract OverviewThe Servicio Andaluz de Salud's central services division ran an open procedure to establish a framework agreement, with reopening of competition, for the harmonised supply of influenza vaccines at a fixed unit price across all SAS centres for the 2026-2027 vaccination campaign, with an option to extend supply into the 2027-2028 campaign. The procurement was divided into five lots and the results were reported across three separate lot result groupings: Lots 1 and 3 together, Lots 2 and 5 together and Lot 4 on its own.Sanofi Aventis, S.A. won the combined Lots 1 and 3, with a tender valued at €14,560,000, following three tenders received. Seqirus Spain, S.L. won the combined Lots 2 and 5, with a tender valued at €21,300,146.40, following two tenders received. Astrazeneca FarmacĂ©utica Spain, S.L. won Lot 4 on its own, with a tender valued at €2,985,746.40, also following two tenders received. All three companies are classified as large economic operators and none of the tenders received across any of the three lot groups came from SMEs or from tenderers registered outside Spain.Key Contract Details Field Detail Contracting authority Servicio Andaluz de Salud. Servicios Centrales Winning suppliers Sanofi Aventis, S.A. (Lots 1 & 3); Seqirus Spain, S.L. (Lots 2 & 5); Astrazeneca FarmacĂ©utica Spain, S.L. (Lot 4) Title Acuerdo Marco Suministro (CONTR 2026 0000087169) CPV code 33651660 – Influenza vaccines Procedure type Open Legal basis Directive 2014/24/EU Maximum framework value (both campaigns, if extended) €47,106,093.00 Value of contracts awarded in this notice €21,300,146.40 (VAT included, per procedure description) Value of Sanofi Aventis tender (Lots 1 & 3) €14,560,000.00 Value of Seqirus Spain tender (Lots 2 & 5) €21,300,146.40 Value of Astrazeneca tender (Lot 4) €2,985,746.40 Contract duration 12 months, with an option for a further 12 month extension Award criteria Price, with additional multiple criteria detailed in tender annexes Framework structure Framework agreement, with reopening of competition Tenders received 3 (Lots 1 & 3); 2 (Lots 2 & 5); 2 (Lot 4), all submitted electronically; 0 from SMEs; 0 from outside Spain EU funding None disclosed GPA coverage Yes Review body Tribunal Administrativo de Recursos Contractuales de la Junta de AndalucĂa Place of performance AndalucĂa, Spain, supplied to all SAS hospitals, health management areas and primary care districts Project ScopeThe framework supplies influenza vaccines to every hospital, health management area and primary care district across the Andalusian public health system for the 2026-2027 seasonal campaign. Regional health officials have stated the initial budget is calibrated to supply approximately 1.955 million doses, with contractual flexibility to expand purchasing by up to 20% depending on how quickly the population is vaccinated, how the flu season develops epidemiologically and evolving clinical need, a built in buffer aimed at supporting a stated ambition to vaccinate more than two million people, prioritising residents over 60, young children, pregnant women and healthcare and care sector workers.Andalusia's current flu immunisation programme uses several distinct vaccine formulations for different population groups: a live attenuated nasal spray vaccine for children roughly 24 to 59 months old, a high antigen dose formulation reserved for institutionalised elderly residents and those aged 80 and above, adjuvanted formulations for immunocompromised adults in certain age bands and standard egg or cell culture derived formulations for the broader population from six months of age onward. The three way split of this framework across Sanofi, Seqirus and AstraZeneca is consistent with each manufacturer supplying the specific formulation types their product portfolios cover within this broader clinical strategy.About the Contracting AuthorityServicio Andaluz de Salud (SAS), the Andalusian Health Service, is the regional authority responsible for public healthcare across Andalusia, Spain's most populous autonomous community. Its central services division coordinates region wide procurement for recurring clinical needs, including the annual flu vaccination campaign, on behalf of the region's full network of hospitals, health management areas and primary care districts.About the Organisations InvolvedSanofi Aventis, S.A., Winning Tenderer (Lots 1 & 3)Sanofi Aventis, headquartered in Barcelona, is the Spanish arm of the French pharmaceutical group Sanofi, a major global vaccine manufacturer with an established flu vaccine portfolio, including its high antigen dose formulation used for elderly and institutionalised populations in several European national and regional immunisation programmes. Classified as a large economic operator, Sanofi's award of the combined Lots 1 and 3 continues an established supply relationship with SAS across previous vaccination campaigns.Seqirus Spain, S.L., Winning Tenderer (Lots 2 & 5)Seqirus, based in Barcelona, is a major global influenza vaccine manufacturer and a subsidiary of Australia's CSL group, known for cell culture based flu vaccine production, a manufacturing method that, unlike traditional egg based production, does not rely on chicken eggs as a growth medium for the vaccine virus. Seqirus's award of the combined Lots 2 and 5, the largest of the three individual tender values in this framework, is consistent with its product covering the broadest population segment within Andalusia's vaccination strategy.Astrazeneca FarmacĂ©utica Spain, S.L., Winning Tenderer (Lot 4)AstraZeneca's Spanish subsidiary, headquartered in Madrid, is the manufacturer of a live attenuated, intranasally administered flu vaccine used specifically for young children in several European immunisation programmes, including Andalusia's, where it is recommended for children between 24 and 59 months of age. The comparatively smaller value of AstraZeneca's single lot award reflects the narrower population segment this specific paediatric formulation serves relative to the broader adult and elderly population covered by the other two winners.Tribunal Administrativo de Recursos Contractuales de la Junta de AndalucĂa, Review OrganisationThe Andalusian Regional Government's Administrative Tribunal for Contractual Appeals, based in Seville, is the designated review body for this procurement, providing the formal legal channel for any bidder wishing to contest aspects of the award across any of the three lot groups.Procurement AnalysisStructuring this framework "with reopening of competition", as opposed to the single supplier, no reopening structure common in patent protected vaccine procurement, reflects the genuine multi product nature of the flu vaccine market. Unlike a single patented biologic with no competing product, seasonal flu vaccines are produced by multiple manufacturers each offering broadly comparable, though not identical, formulations for different population segments, allowing SAS to run a genuinely competitive process across five lots rather than defaulting to a sole source justification.The three way lot allocation pattern is also informative. Rather than every lot going to a different single winner, two of the three manufacturers each won a combined pair of lots (Sanofi taking Lots 1 and 3 together, Seqirus taking Lots 2 and 5 together), while AstraZeneca won a single lot on its own, a pattern consistent with manufacturers bidding successfully across multiple lots suited to their specific product range, rather than the lots being contested independently by entirely different sets of competitors each time.One notable feature worth flagging plainly: the notice's recorded "value of all contracts awarded in this notice" figure, €21,300,146.40, is identical to the individual tender value recorded for Seqirus's Lots 2 and 5 award alone. Summing all three individual winning tender values recorded elsewhere in the same notice, Sanofi's €14,560,000, Seqirus's €21,300,146.40 and AstraZeneca's €2,985,746.40, produces a considerably higher total of approximately €38.85 million. Public reporting on this same procurement cites the total flu vaccine acquisition cost for the 2026-2027 campaign at approximately €21.3 million, matching the notice's aggregate field rather than the sum of the three individual tenders.Additional Procurement FactsNone of the tenders received across any of the three lot groups came from SMEs, from tenderers registered in other EEA countries or from non EEA bidders, all six tenders received across the three groups were submitted by large, Spain registered pharmaceutical companies, consistent with the concentrated nature of the global flu vaccine manufacturing market. No subcontracting was disclosed for any of the three winning tenders. The contract carries no EU funding, is financed entirely through Andalusia's regional health budget and is confirmed as covered by the WTO Government Procurement Agreement.Market & Industry PerspectiveThe global influenza vaccine market is served by a relatively small group of large manufacturers, including Sanofi, Seqirus (CSL), AstraZeneca, GSK and others, each typically specialising in specific formulation types: standard inactivated vaccines, cell culture based production, high antigen dose formulations for elderly populations, adjuvanted formulations for immunocompromised groups and live attenuated nasal formulations for children. Regional and national health authorities across Europe routinely split flu vaccine procurement across multiple manufacturers precisely because no single company's product range typically covers every population segment a comprehensive vaccination programme needs to reach.Andalusia's specific three way split in this framework, a broad population cell based vaccine from Seqirus, elderly focused and general adult formulations from Sanofi and a paediatric nasal vaccine from AstraZeneca, is a fairly standard structure for a well developed regional flu immunisation programme and is broadly consistent with how other large Spanish autonomous communities structure comparable annual flu vaccine procurement.Economic SignificanceAt a combined value of just over €21.3 million for the base 2026-2027 campaign, rising to a maximum framework ceiling of €47.1 million if extended into the 2027-2028 season, this is one of Andalusia's largest annual recurring vaccine procurement categories. Regional officials have described the coming campaign as record setting in scale, with an initial budget calibrated for approximately 1.955 million doses and contractual flexibility to expand purchasing by up to a further 20% depending on vaccination uptake and epidemiological developments through the season, underscoring both the scale of the region's public health commitment to flu prevention and the built in supply flexibility this framework structure is designed to provide.For the three winning manufacturers, the award represents continued, substantial revenue from one of Spain's largest regional health systems, split according to each company's specific position within Andalusia's broader flu vaccination strategy.Future Procurement OpportunitiesWith an option to extend supply into the 2027-2028 campaign already built into this framework, the next genuinely open competition for Andalusia's flu vaccine supply is not likely to reach the market again until at least the 2028-2029 season, assuming the extension option is exercised. In the interim, suppliers should watch for potential additional call offs within the existing framework's 20% supply expansion flexibility, should vaccination uptake or epidemiological conditions during the 2026-2027 campaign warrant it.Opportunities for SuppliersManufacturers with flu vaccine formulations not currently represented in this framework, including adjuvanted formulations for specific immunocompromised populations or newer formulation technologies, should watch for the framework's next open competition, whenever the extension option lapses or is not exercised. Given Andalusia's demonstrated pattern of splitting its flu vaccine procurement across multiple manufacturers by population segment, a supplier with a genuinely differentiated product targeting an underserved population group has a credible route to winning a future lot, rather than needing to displace an incumbent across the entire framework.What Businesses Should WatchThree developments are worth tracking. First, whether Andalusia exercises its 20% supply expansion option during the 2026-2027 campaign and how that additional demand is allocated among the three winning manufacturers. Second, whether the option to extend the framework into the 2027-2028 campaign is exercised, which would delay the next open competition by a further year. Third, whether the apparent discrepancy between the notice's aggregate contract value and the sum of its three individual tender values is clarified in any subsequent corrigendum or related notice, since that detail matters for anyone tracking the precise scale of this procurement category.SpainTenders.com Procurement IntelligenceThis framework is a clean illustration of how mature seasonal vaccination programmes structure procurement once a single product can no longer serve an entire target population. Rather than treating "flu vaccine" as one interchangeable commodity andalusia's framework explicitly segments its population by age, health status and care setting, then allocates supply lots to whichever manufacturers' specific formulations best serve each segment, a considerably more clinically sophisticated procurement structure than a simple lowest price, single supplier award would allow.The apparent gap between the notice's headline aggregate value and the sum of its three individual winning tenders is worth treating as a genuine data quality flag rather than dismissing it. Procurement notices of this complexity, spanning multiple lots and multiple winners reported across grouped result sections, carry real risk of aggregation errors in how totals are calculated and published, a reminder that readers relying on headline summary figures in TED notices should cross check against the underlying lot level detail wherever precision matters, particularly for notices this structurally complex.Looking ahead, the built in 20% supply flexibility clause is itself a notable design feature worth watching more broadly: as flu seasons become less predictable and vaccination campaigns are increasingly run alongside COVID 19 and RSV immunisation efforts, expect more regional health authorities to build similar volume flexibility provisions directly into their base vaccine procurement contracts, rather than treating supply expansion as a separate, later negotiation.Supplier Takeaways Mature seasonal vaccination programmes increasingly split procurement across multiple manufacturers by population segment rather than awarding a single supplier, a genuinely differentiated formulation targeting an underserved group has a real route to winning a lot. Framework agreements with reopening of competition, as used here, remain the standard structure for flu vaccines specifically, distinct from the single supplier, no reopening structure common for patent protected vaccines with no comparable competing product. Built in volume flexibility clauses (here, up to 20% additional supply) are becoming a standard feature of seasonal vaccine contracts, suppliers should price and plan capacity with this flexibility in mind. All bidders across this specific competition were large, Spain registered pharmaceutical companies; no SME or non Spanish EEA participation was recorded. Watch for the framework's extension option (into the 2027-2028 campaign) and its impact on when the next open competition reaches the market. Key Takeaways The Servicio Andaluz de Salud awarded its 2026-2027 flu vaccine framework across three manufacturers: Sanofi Aventis (Lots 1 & 3, €14.56 million), Seqirus Spain (Lots 2 & 5, €21.3 million) and Astrazeneca FarmacĂ©utica Spain (Lot 4, €2.99 million). The framework carries a maximum ceiling of €47.1 million if extended into the 2027-2028 campaign, with a base 12 month term and a 12 month extension option. All six tenders received across the three lot groups came from large, Spain registered pharmaceutical companies; none from SMEs or non Spanish bidders. Andalusia is targeting more than two million vaccinated residents this campaign, with an initial budget for roughly 1.955 million doses and flexibility to expand supply by up to 20%. ConclusionA flu shot might look the same to most patients rolling up a sleeve at their local health centre, but behind that single act sits a genuinely complex, multi manufacturer supply chain built to match the right formulation to the right person. Andalusia's three way vaccine split, one supplier for the very young, one for the frail elderly, one for the broader population in between, is what a well designed public vaccination programme looks like when it takes population diversity seriously rather than treating every patient as interchangeable. Source: EU Official Journal, Contract Award Notice 504488-2026, OJ S 138/2026, published 21/07/2026. Contracting authority: Servicio Andaluz de Salud, Servicios Centrales.
View Details
Andalusia Locks In €23 Million of HPV Vaccine From a Single Supplier, Because, Legally, There Was No Other Choice
20 Jul 2026
Standfirst The Andalusian Health Service has awarded a framework agreement worth up to €28.8 million to Merck Sharp & Dohme de España for the region's entire supply of nonavalent HPV vaccine over the next two years. There was only one bidder and there could only ever have been one: the vaccine is patent protected and Andalusia's health authorities determined no competing product could satisfy the programme's requirements. Introduction Most public procurement stories are about competition, who beat whom and by how much. This one is about the absence of competition and why that absence is entirely lawful, deliberate and in this case, medically necessary. The Andalusian Health Service (Servicio Andaluz de Salud or SAS) has formally awarded its supply contract for the nonavalent human papillomavirus vaccine, sold under the brand name Gardasil 9, to Merck Sharp & Dohme de España, the Spanish subsidiary of the American pharmaceutical group Merck. The contract runs for 24 months, carries an estimated ceiling of €28.78 million and was procured through a negotiated procedure without a prior call for competition, a legal route reserved for exactly this kind of situation, where a contracting authority can demonstrate that only one economic operator is capable of supplying what is required, typically because of exclusive intellectual property rights. A single tender was submitted, for a value of just over €23 million and that tender was, by definition, the only one that could have been. Why This Contract Matters Andalusia has run a universal HPV vaccination programme since well before this contract, offering the vaccine to both boys and girls around age 12, with catch up vaccination extended to young people up to 21. Since April 2021, Gardasil 9, the nonavalent formulation protecting against nine strains of the virus, including the two, types 16 and 18, responsible for the large majority of HPV related cervical cancers, has been the only HPV vaccine used across the region's public vaccination programme, for both routine adolescent vaccination and vaccination of higher risk groups. That clinical decision to standardise on a single vaccine formulation has a direct procurement consequence: once a health authority commits to a specific, patented vaccine as its standard of care, it cannot simply switch suppliers or invite alternative products to compete on price, because no equivalent, interchangeable product exists on the market. This contract is what that commitment looks like in procurement terms, a legally justified single supplier award, sized to keep Andalusia's vaccination programme supplied for the next two years. Contract Timeline Date Milestone April 2021 Andalusia adopts the nonavalent HPV vaccine (Gardasil 9) as the sole vaccine used in its regional immunisation programme 19 June 2026 Winner selected 15 July 2026 Contract concluded with Merck Sharp & Dohme de España, S.A. 16 July 2026 Award notice dispatched to the EU Publications Office 20 July 2026 Notice published in OJ S 137/2026 Through mid 2028 24 month supply period under this framework agreement Contract Overview The Servicio Andaluz de Salud's central services division ran a negotiated procedure without prior call for competition to establish a single supplier framework agreement for successive supply of nonavalent HPV vaccine at a fixed unit price, intended for Andalusia's regional vaccination programme. The justification recorded in the notice is unambiguous: the contract can be provided only by a particular economic operator because of exclusive rights, including intellectual property rights and Andalusian health authorities determined that no genuine competition was technically possible for this specific supply. One tender was received, the only one that could be, given the sole source justification, submitted electronically by Merck Sharp & Dohme de España, for a contract value of €23,025,600, against an estimated ceiling of €28,782,000 for the full 24 month framework term. Key Contract Details Field Detail Contracting authority Servicio Andaluz de Salud. Servicios Centrales Winning supplier Merck Sharp & Dohme de España, S.A. Title Contrato de Suministro (CONTR 2025 0000096959) CPV code 33651600 – Vaccines Procedure type Negotiated without prior call for competition Legal basis Directive 2014/24/EU; Spanish Public Sector Contracts Law (LCSP), Article 168.a).2ÂŞ Justification for direct award Exclusive rights, including intellectual property rights, no technical competition possible Estimated framework value (24 months) €28,782,000 Awarded contract value €23,025,600 Contract duration 24 months Award criterion Price (further detail reserved to the tender specifications, "PCAP") Framework structure Framework agreement with a single company, without reopening of competition Tenders received 1, submitted electronically Subcontracting No EU funding None disclosed GPA coverage Yes Review body Tribunal Administrativo de Recursos Contractuales de la Junta de AndalucĂa Place of performance AndalucĂa, Spain Project Scope The framework covers ongoing, successive supply of nonavalent HPV vaccine at a fixed unit price to Andalusia's regional vaccination programme over a 24 month period. As the sole vaccine formulation used in the programme since 2021, Gardasil 9 is administered to adolescents around age 12 as part of universal vaccination offered to both sexes, alongside catch up doses for young people up to 21 who have not yet completed a vaccination course and use in specific higher risk clinical groups at other ages where indicated. The regional programme has stated an ambition to reach at least 90% vaccination coverage across both sexes. The notice does not disclose the specific number of doses covered under this framework, nor the unit price per dose; readers seeking that level of operational detail should consult SAS's own published contract documentation. About the Contracting Authority Servicio Andaluz de Salud (SAS), the Andalusian Health Service, is the regional authority responsible for public healthcare provision across Andalusia, Spain's most populous autonomous community. Its central services division manages large scale, region wide procurement, including pharmaceutical and vaccine supply, on behalf of the region's public hospitals and primary care network. Vaccine procurement of this kind sits within SAS's broader public health mandate, ensuring consistent, uninterrupted vaccine supply across a region serving a population of more than eight million people. About the Organisations Involved Merck Sharp & Dohme de España, S.A., Winning Tenderer Merck Sharp & Dohme de España is the Spanish subsidiary of Merck & Co. (known outside the United States and Canada as MSD), the American pharmaceutical group that manufactures Gardasil 9, the only nonavalent HPV vaccine currently authorised and marketed in Spain. Classified as a large economic operator and headquartered in Madrid, the company holds the patent and manufacturing rights underlying the vaccine, which is precisely the basis on which Andalusian health authorities determined a competitive tender was not legally or technically possible for this supply. Tribunal Administrativo de Recursos Contractuales de la Junta de AndalucĂa, Review Organisation The Andalusian Regional Government's Administrative Tribunal for Contractual Appeals, based in Seville, is the designated body for hearing legal challenges against public procurement decisions taken by Andalusian regional authorities, including this direct award. Its role is to provide a formal review channel, separate from SAS itself, for any party wishing to contest the justification for this sole source procurement. Procurement Analysis The use of a negotiated procedure without prior call for competition, justified by exclusive intellectual property rights, is a narrowly defined and closely scrutinised route within EU and Spanish procurement law, reserved for situations where a contracting authority can demonstrate that genuine market competition is technically impossible, not merely impractical or inconvenient. In this case, the justification rests on Andalusia's clinical commitment to a single, patented vaccine formulation: because Gardasil 9 has no directly interchangeable competitor product authorised for the same indications and used within the region's standardised vaccination protocol, SAS determined that inviting alternative bids would not produce a genuine competitive process. This is a structurally different situation from a poorly run or under competed tender. The single bid received here is not evidence of weak market interest or a failure to attract suppliers; it is the direct, intended consequence of a sole source justification that, by design, permits only one legitimate bidder to participate. The award criterion remains price, but with only one qualifying supplier, that price is effectively negotiated between SAS and Merck directly, within the bounds of the framework's fixed unit price structure, rather than tested against competing offers. Additional Procurement Facts The single tender received was submitted electronically and no tenders were recorded from SMEs, other EEA registered tenderers or non EEA bidders, an expected outcome given the sole source justification restricting the field to one qualifying supplier by design. No subcontracting is disclosed for the winning tender. The contract carries no EU funding, is financed entirely through Andalusia's own regional health budget and is confirmed as covered by the WTO Government Procurement Agreement despite being procured without competitive tendering. Market & Industry Perspective The global HPV vaccine market remains highly concentrated, dominated by two vaccine formulations: Merck's nonavalent Gardasil 9 and GSK's bivalent Cervarix, with earlier quadrivalent Gardasil formulations largely superseded. Since Andalusia adopted Gardasil 9 as its sole HPV vaccine for both universal and risk group vaccination in 2021, the region, in common with most other Spanish autonomous communities and many European national immunisation programmes, has effectively locked its HPV vaccination strategy to a single manufacturer's product, a pattern replicated across multiple regional health systems in Spain given Gardasil 9's broader strain coverage compared with bivalent alternatives. This concentration is a direct feature of the vaccine market generally: patent protected biologics with strong clinical differentiation, such as broader spectrum HPV vaccines, routinely produce single supplier procurement outcomes of exactly this kind across European public health systems, since generic or biosimilar competition is not available for vaccines still under active patent protection. Economic Significance At an estimated ceiling of €28.78 million and an awarded value of just over €23 million for two years of supply, this is a substantial, recurring category of regional public health spending, reflecting both the scale of Andalusia's population and its commitment to broad, universal HPV vaccination coverage across both sexes. For Merck Sharp & Dohme, the contract represents continued, secure revenue from one of Spain's largest regional health systems, extending a supply relationship that has been in place since Andalusia adopted the nonavalent vaccine in 2021. For Andalusian public health more broadly, locking in a fixed unit price supply framework for 24 months provides budgetary predictability for a vaccination programme central to the region's cervical and HPV related cancer prevention strategy, insulating the programme's cost base from short term price volatility over the framework's term. Future Procurement Opportunities Because this contract's sole source status stems directly from Andalusia's clinical adoption of a specific, patented vaccine, the most significant lever for future competitive procurement in this category is not this framework's renewal, but any future change in the region's clinical vaccination protocol, for instance, if a new, clinically comparable HPV vaccine formulation from a different manufacturer receives Spanish regulatory authorisation and is adopted as an alternative or replacement within the regional programme. Absent such a change, subsequent renewals of this supply arrangement are likely to continue following the same single supplier, negotiated procedure structure. Opportunities for Suppliers For pharmaceutical manufacturers, this notice is a clear illustration of how thoroughly clinical protocol decisions can determine procurement outcomes years in advance. Competing vaccine manufacturers seeking to displace an incumbent sole source supplier in a category like this must generally succeed first at the clinical and regulatory level, securing Spanish and regional health authority adoption of their product into the standard vaccination protocol, before any genuine procurement competition becomes possible. Suppliers of vaccine cold chain logistics, storage and distribution services tied to regional immunisation programmes may find more immediately accessible adjacent opportunities, given the vaccine's specific 2°C–8°C storage requirements referenced in Andalusia's own clinical guidance. What Businesses Should Watch Three things are worth tracking in this category. First, whether any competing nonavalent or broader coverage HPV vaccine formulation gains Spanish regulatory authorisation and clinical adoption that could eventually introduce competition into Andalusia's procurement for this vaccine category. Second, how Andalusia's vaccination coverage rates trend against its stated 90% target across both sexes, since sustained progress toward that goal would likely support continued or expanded procurement volumes in future framework renewals. Third, whether other Spanish autonomous communities' HPV vaccine procurement, most of which similarly rely on Gardasil 9 as their standard formulation, shows any sign of diverging from this single supplier pattern. SpainTenders.com Procurement Intelligence This notice is a useful reminder that not every single bidder procurement result reflects a weak or poorly run competition, some are the direct, lawful and entirely predictable outcome of a sole source justification built on patent exclusivity, particularly common across pharmaceutical and vaccine procurement in European public health systems. The real competitive dynamic in categories like this one plays out years earlier, at the clinical and regulatory level, when a health authority decides which vaccine formulation to adopt as its programme standard. Once that decision is made, as Andalusia's was in 2021, in favour of the broader coverage nonavalent formulation, the procurement outcome for years of subsequent supply contracts is effectively determined in advance. For suppliers and market observers, the more informative signal to track in this category is not this specific award, but any shift in the underlying clinical landscape: new vaccine formulations gaining regulatory approval, changes in national or regional immunisation guidelines or shifts in how health authorities balance vaccine breadth of protection against acquisition cost. Those are the genuine inflection points that could eventually reopen genuine competition in a category that, for now, remains structurally locked to a single manufacturer. The administrative gap around the framework's originating notice reference is a smaller, but still worthwhile, data quality point: it is a reminder that even within the EU's standardised TED notice system, cross referencing between related notices does not always function cleanly and researchers relying on notice to notice traceability should treat such references with appropriate caution. Supplier Takeaways Sole source, patent justified procurement is a routine and lawful feature of European vaccine and pharmaceutical public procurement, a single bidder in these categories does not indicate a flawed process. The genuine competitive battleground for vaccine categories like this one is clinical and regulatory adoption, not the procurement tender itself; competing manufacturers must first secure inclusion in a health authority's standard vaccination protocol. Regional Spanish health systems, including Andalusia, have broadly standardised on Merck's nonavalent Gardasil 9 for HPV vaccination since 2021, creating a durable, multi year single supplier procurement pattern across the country. Adjacent opportunities in cold chain logistics and vaccine distribution services remain open to competition even where the vaccine product itself is sole sourced. Watch for regulatory and clinical developments, new vaccine formulations or updated national guidelines, as the real signal of when genuine competitive procurement could return to this category. Key Takeaways The Servicio Andaluz de Salud awarded a 24 month, single supplier framework agreement for nonavalent HPV vaccine to Merck Sharp & Dohme de España, valued at up to €28.78 million, with the awarded contract itself worth €23,025,600. The award was made through a negotiated procedure without prior call for competition, justified by Merck's exclusive intellectual property rights over the vaccine. Only one tender was received, consistent with the sole source justification restricting the field to a single qualifying supplier. Andalusia has used Gardasil 9 as its sole HPV vaccine for universal adolescent and risk group vaccination since April 2021, targeting at least 90% coverage across both sexes. The contract carries no EU funding but is confirmed as covered by the WTO Government Procurement Agreement. Conclusion Not every procurement story is about who won a competition, some are about why a competition was never possible in the first place and what that says about how modern public health systems manage patented medical technology. Andalusia's HPV vaccine contract is a clean example: a regional health authority committed years ago to a specific, broader protection vaccine formulation and every subsequent supply contract since has followed, lawfully and predictably, from that single clinical decision. For the roughly two million adolescents and young people the region aims to protect against HPV related cancers, that consistency is very much the point. Source: EU Official Journal, Contract Award Notice 499270-2026, OJ S 137/2026, published 20/07/2026. Contracting authority: Servicio Andaluz de Salud, Servicios Centrales.
View Details